Description: Ocuphire is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation, and commercialization of drugs in key global markets.
Home Page: www.ocuphire.com
OCUP Technical Analysis
37000 Grand River Avenue
Farmington Hills,
MI
48335
United States
Phone:
248 681 9815
Officers
| Name | Title |
|---|---|
| Ms. Mina Patel Sooch M.B.A., MBA | Founder, CEO, Pres, Treasurer & Vice Chair of the Board |
| Ms. Amy Zaremba Rabourn C.P.A., CPA, MAcc | VP of Fin. & Principal Accounting Officer |
| Mr. Bernhard Hoffmann M.B.A. | VP of Corp. Devel. & Operations and Sec. |
| Dr. Daniela C. Oniciu Ph.D. | Global Head of R&D, Chemistry and Product Devel. |
| Dr. Mitchell Brigell Ph.D. | Head of Clinical Devel. & Strategy |
| Mr. Chris Ernst | Global Head of QA & Manufacturing |
| Ms. Bindu Manne | Head of Market Devel. & Commercialization |
| Mr. Erik Sims | Director & Corp. Controller |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.3958 |
| Price-to-Sales TTM: | 92.1672 |
| IPO Date: | 2005-05-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |